Global Recombinant Plasma Protein Therapeutics Market 2021: Global Industry Analysis Report to 2027
The global recombinant plasma protein therapeutics market is expected to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are leading to the growth of the global recombinant plasma protein therapeutics market include the increasing prevalence of autoimmune disorders, immune deficiency disorders, neurological and bleeding disorders. Along with these factors, the rise in the geriatric population across the globe is a major reason for market growth, as elderly people are more prone to neurological disorders. Furthermore, the growing investments in research and development programs by biotechnology and pharmaceutical companies are boosting the market growth.
There has been an increase in
the number of regulatory approvals in the last three years that have increased
the availability of various options for patients with rare diseases such as
haemophilia and other bleeding disorders. These approvals enabled companies to
expand their product portfolios and gain a competitive advantage in the global
recombinant plasma protein therapeutics market during the forecast period.
To Request a Sample of our Report on Global Recombinant Plasma Protein Therapeutics Market: https://www.omrglobal.com/request-sample/recombinant-plasma-protein-therapeutics-market
The global recombinant plasma protein therapeutics
market analysis includes some of the key market players such as Takeda
Pharmaceutical Company Ltd, Octapharma USA Inc., Grifols, SA, CSL Behring,
Biotest AG, and Baxter, among others. To maintain a strong position in the
market, these market players are adopting various strategic moves, such as
product launches, partnerships, collaborations, and mergers and
acquisitions.
Recent Developments:
·
In February 2021, Biotest became Germany's first plasma
protein manufacturer to produce an investigational hyper immunoglobulin
preparation against COVID-19.
·
In July 2020, Grifols SA signed an agreement with GC
Pharma Group to acquire its Montreal-based plasma fractionation facility and
two purification facilities with 11 United States-based plasma collection
centers.
Market Coverage
·
The market number available for – 2020-2027
·
Base year- 2020
·
Forecast period- 2021-2027
·
Segment Covered
·
Regions Covered- Globally
·
Competitive Landscape: Takeda Pharmaceutical Company Ltd, Octapharma
USA Inc., Grifols, SA, CSL Behring, Biotest AG, and Baxter, among others.
(Get 15% Discount on Buying this Report)
A
full Report of Global Recombinant Plasma Protein Therapeutics Market is
Available at: https://www.omrglobal.com/industry-reports/recombinant-plasma-protein-therapeutics-market
Global Recombinant Plasma Protein Therapeutics Market by Segment
By Product
• Immunoglobulin
• Albumin
• Plasma Derived Factor
Viii
• Other
By Application
• Hemophilia
• Idiopathic
Thrombocytopenic Purpura
• Primary
Immunodeficiencies
• Other
Global Recombinant Plasma Protein Therapeutics Market by Region
North America
·
United States
·
Canada
Europe
·
UK
·
Germany
·
Spain
·
France
·
Italy
·
Rest of Europe
Asia-Pacific
·
India
·
China
·
Japan
·
South Korea
·
Rest of APAC
Rest of the World
Reasons to buy from us –
1. We cover more than
15 major industries, further segmented into more than 90 sectors.
2. More than 120
countries are for analysis.
3. Over 100+ paid
data sources mined for investigation.
4. Our expert
research analysts answer all your questions before and after purchasing your
report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company
known for its crisp and concise reports. The company is equipped with an
experienced team of analysts and consultants. OMR offers quality syndicated
research reports, customized research reports, consulting and other
research-based services.
Media
Contact:
Company
Name: Orion Market Research
Contact
Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact
no: +91 7803040404
Comments
Post a Comment